From the Journals

Potential New Lyme Disease Therapy Advances to Human Safety Trials

The novel antibiotic therapy hygromycin A has advanced to human safety trials to determine its potential as a future treatment for Lyme disease.

Share

The novel antibiotic therapy, hygromycin A, has advanced to human safety trials as a potential future treatment for Lyme disease. It is designed to target spirochetes bacteria, including Borrelia burgdorferi, and may eliminate residual pathogens that lead to chronic Lyme disease. Positive safety findings in preclinical models have led to upcoming human trials in Australia, expected to conclude in the fall of 2024, with hopes for positive results. - Kim Lewis, PhD, Distinguished Professor of Biology at the Northeastern University College of Science

Original Source(s)

Potential New Lyme Disease Therapy Advances to Human Safety Trials

The novel antibiotic therapy hygromycin A has advanced to human safety trials to determine its potential as a future treatment for Lyme disease.

  • by Conexiant News Staff

  • April 30, 2024

  • 1 min

Related Content

Anti-CD146 Linked to Silica in Systemic Sclerosis

Comparative analysis across exposed workers, cancer controls, and healthy donors supports specificity.

Drooling Flags Severe Dermatomyositis

Three cases suggest drooling may mark advanced dermatomyositis with dysphagia, aspiration pneumonia, and poor response to treatment.

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.